Correspondence 0001493152-23-004544 from ZyVersa Therapeutics, Inc. (ZVSA)

ZyVersa Therapeutics, Inc.
Date: Feb. 13, 2023 · CIK: 0001859007 · Accession: 0001493152-23-004544

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-269442

Date

Feb. 13, 2023

Author

ZYVERSA

Form

CORRESP

Company

ZyVersa Therapeutics, Inc.

Letter

VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences File No. 333-269442 Acceleration Request Requested Date: February 14, 2023 Requested Time: 4:30 p.m., Eastern Time

Dear Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, ZyVersa Therapeutics, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission (the “Commission”) at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Commission.

Please call Jared Kelly of Lowenstein Sandler LLP at (212) 419-5974 to confirm the effectiveness of the Registration Statement or with any questions.

Sincerely,
ZYVERSA
THERAPEUTICS, INC.

Show Raw Text

CORRESP
1
filename1.htm

February
13, 2023

VIA
EDGAR

United
States Securities and Exchange Commission

Division
of Corporation Finance

Office
of Life Sciences

Mail
Stop 4720

100
F Street, N.E.

Washington,
D.C. 20549

Attn:
Lauren Hamill

Laura
Crotty

    Re:
    ZyVersa Therapeutics, Inc.

    Registration Statement on Form S-1, as amended

    File No. 333-269442

    Acceleration
    Request

    Requested
    Date:
    February
    14, 2023

    Requested
    Time:
    4:30
    p.m., Eastern Time

Dear
Ladies and Gentlemen:

Pursuant
to Rule 461 under the Securities Act of 1933, as amended, ZyVersa Therapeutics, Inc. (the “Company”) hereby requests that
the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange
Commission (the “Commission”) at the “Requested Date” and “Requested Time” set forth above or at
such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance
of the Commission.

Please
call Jared Kelly of Lowenstein Sandler LLP at (212) 419-5974 to confirm the effectiveness of the Registration Statement or with any questions.

    Sincerely,

    ZYVERSA
    THERAPEUTICS, INC.

    By:
    /s/
    Stephen C. Glover

    Name:
    Stephen
    C. Glover

    Title:
    Chief
    Executive Officer

SecProbe.io